RT Book, Section
A1 Dall’Era, Maria
A2 Stone, John H.
SR Print(0)
ID 1180196547
T1 Systemic Lupus Erythematosus
T2 Current Diagnosis & Treatment: Rheumatology, 4e
YR 2021
FD 2021
PB McGraw Hill
PP New York, NY
SN 9781259644641
LK accessmedicine.mhmedical.com/content.aspx?aid=1180196547
RD 2024/04/24
AB Predilection  for  females  of  childbearing  age.Multisystem  disease  that  has  a  tendency  to  remit  and  relapse.Photosensitive  rash,  polyarthritis,  serositis,  and  fatigue  are  common  flare  manifestations.Renal  disease,  central  nervous  system  involvement,  and  complications  of  antiphospholipid  antibodies  can  cause  major  morbidity.Treatment-related  morbidity,  particularly  from  glucocorticoids,  constitutes  a  major  source  of  damage  associated  with  having  lupus.Presence  of  antinuclear  antibodies.Certain  autoantibodies  (anti-dsDNA  and  anti-Sm)  have  great  specificity  for  the  diagnosis  of  systemic  lupus  erythematosus  (SLE)  but  lack  sensitivity.Hypocomplementemia  may  occur  during  flares.